V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papillomavirus Infection
Conditions
Human Papillomavirus Infection
Trial Timeline
Oct 21, 2009 → Feb 22, 2011
NCT ID
NCT00988884About V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant) is a phase 3 stage product being developed by Merck for Human Papillomavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00988884. Target conditions include Human Papillomavirus Infection.
What happened to similar drugs?
14 of 20 similar drugs in Human Papillomavirus Infection were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00988884 | Phase 3 | Completed |
Competing Products
20 competing products in Human Papillomavirus Infection